Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for treating limited-stage small-cell lung cancer (SCLC) after chemoradiation.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 5073
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- AstraZeneca (durvalumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- British Thoracic Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 June 2025 | Committee meeting |
| 10 December 2024 | The timelines for this appraisal have been revised slightly. The committee meeting will now be held on 12 June 2025. |
| 02 October 2024 | Invitation to participate |
| 10 July 2024 - 07 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5073 |
| 10 July 2024 | In progress. Scoping commenced. |
| 20 June 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2024. |
| 22 February 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual